Obtained FDA Approval for EYSUVISTM, First Prescription Therapy Approved Specifically for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
EYSUVIS Expected to Begin Shipping to Wholesalers by End of 2020
3Q 2020 INVELTYS® Net Revenue of $2.2 Million
Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 3Q 2022 EYSUVIS Revenue Expected to Provide Additional Runway
#KALA "reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.
Third Quarter and Recent Highlights:
EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%: On October 26, 2020, the U.S. Food and Drug Administration (FDA) approved EYSUVIS for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease (DED). The FDA granted approval for EYSUVIS based on results from four clinical trials that enrolled over 2800 patients and demonstrated rapid and significant improvements in both the signs and symptoms of dry eye disease. EYSUVIS was well-tolerated across the four trials, with adverse events and intraocular pressure increases comparable to that observed with vehicle (placebo).
INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%: Approximately 38,000 INVELTYS prescriptions were reported by Symphony Health in the third quarter of 2020, which represents an increase of approximately 84% compared to the second quarter of 2020. Relatedly, cataract procedures increased in the third quarter compared to the second quarter of 2020, reflecting the resumption of ocular surgeries as COVID-19-related restrictions on elective procedures began to relax late in the second quarter" (see press release HERE).
See our KALA AmpCards to learn more.